A3874F0D-53A9-43C8-87EE-65C12C0F8135
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.734
- INTERFERON_GAMMA_RESPONSE+0.690
- ALLOGRAFT_REJECTION+0.676
- IL6_JAK_STAT3_SIGNALING+0.657
- TNFA_SIGNALING_VIA_NFKB+0.594
- INFLAMMATORY_RESPONSE+0.588
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.569
- IL2_STAT5_SIGNALING+0.526
- COMPLEMENT+0.509
- ANGIOGENESIS+0.503
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.324
- SPERMATOGENESIS-0.323
- KRAS_SIGNALING_DN-0.251
- HEDGEHOG_SIGNALING-0.166
- E2F_TARGETS-0.038
- MYC_TARGETS_V1-0.010
- G2M_CHECKPOINT+0.018
- OXIDATIVE_PHOSPHORYLATION+0.053
- MITOTIC_SPINDLE+0.065
- PEROXISOME+0.077
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.972 |
| 2 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.945 |
| 3 | CB1F8B9C-7CE7-4181-B746-7FC697ED27F4 | — | — | 0.943 |
| 4 | SRR934811 | — | — | 0.943 |
| 5 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.941 |
| 6 | SRR934729 | — | — | 0.941 |
| 7 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.940 |
| 8 | SRR934845 | — | — | 0.939 |
| 9 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.937 |
| 10 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.734 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.690 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.676 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.657 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.594 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.588 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.569 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.526 | Idelalisib | — uncovered |
| COMPLEMENT | 0.509 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.503 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.502 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.498 | Inavolisib | — uncovered |
| COAGULATION | 0.463 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.418 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.389 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.373 | Inavolisib | — uncovered |
| HYPOXIA | 0.355 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.312 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.309 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.306 | Inavolisib | — uncovered |